CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Celyad Oncology Sa  (CYAD)
Other Ticker:  
 

Celyad Oncology Sa's Total Debt to Equity

CYAD's quarterly Total Debt to Equity and Total Debt, Equity growth


Due to debt repayement of 0% Celyad Oncology Sa improved Total Debt to Equity in forth quarter 2022 to 0.06, a new company high.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 39 other companies have achieved lower Total Debt to Equity than Celyad Oncology Sa in the IV Quarter 2022. While Total Debt to Equity total ranking has deteriorated compared to the third quarter 2022 from 441 to 448 .

Explain Debt to Equity Ratio?
What is the structure of CYAD´s Total Debt?
How valuable is the CYAD´s Equity?


CYAD Total Debt to Equity (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change -90.11 % -90.11 % -90.11 % -90.11 % 40.8 %
Y / Y Total Debt Change 57.32 % 57.32 % 57.32 % 57.32 % -59.8 %
Total Debt to Equity MRQ 0.06 0.06 0.06 0.06 0
CYAD's Total Ranking # 448 # 441 # 440 # 441 # 106
Seq. Equity Change 0 % 0 % 0 % -90.11 % 0 %
Seq. Total Debt Change 0 % 0 % 0 % 57.32 % 0 %

New: More CYAD's historic Total Debt to Equity Ratios >>


Total Debt to Equity forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 94
Overall Market # 448


Total Debt to Equity Statistics
High Average Low
0.06 0.02 0
(Dec 31 2022)   (Dec 31 2021)




Financial Statements
Celyad Oncology Sa's Equity $ 5 Millions Visit CYAD's Balance sheet
Celyad Oncology Sa's Total Debt $ 0 Millions Visit CYAD's Balance sheet
Source of CYAD's Sales Visit CYAD's Sales by Geography


Cumulative Celyad Oncology Sa's Total Debt to Equity

CYAD's Total Debt to Equity for the trailling 12 Months

CYAD Total Debt to Equity

 (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -90.11 % -90.11 % -90.11 % -90.11 % 40.8 %
Y / Y Total Debt TTM Growth 57.32 % 57.32 % 57.32 % 57.32 % -59.8 %
Total Debt to Equity TTM 0.06 0.02 0.01 0.01 0
Total Ranking TTM # 539 # 250 # 182 # 177 # 159
Seq. Equity TTM Growth 0 % 0 % 0 % -90.11 % 0 %
Seq. Total Debt TTM Growth 0 % 0 % 0 % 57.32 % 0 %

Debt to equity ratio ranking by company, industry and sector >> Back to CYAD Financial Strength Comparisons >> Go to Compare CYAD Total Debt to Equity Ratio to its Competitors

On the trailing twelve months basis Despite of the debt repayement of 0% in the trailing twelve months ending in IV Quarter 2022, Total Debt to Equity improved to 0.06, a new company high.
Total Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 3, during the past 12 months, other companies have achieved lower Total Debt to Equity than Celyad Oncology Sa. While Total Debt to Equity total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 12 to 521.

Explain Debt to Equity Ratio?
What is the structure of CYAD´s Total Debt?
How valuable is the CYAD´s Equity?

TTM Total Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 4
Healthcare Sector # 4
Within the Market # 448


trailing twelve months Total Debt to Equity Statistics
High Average Low
0.06 0.01 0
(Dec 31 2022)   (Dec 31 2021)




Companies with similar Total Debt to Equity in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Total Debt to EquityDec 31 2022 MRQ Total DebtDec 31 2022 MRQ Equity
Kineta Inc   0.16 $ 0.748  Millions$ 4.570  Millions
Actinium Pharmaceuticals Inc   0.15 $ 10.130  Millions$ 66.481  Millions
Cue Biopharma Inc   0.15 $ 9.998  Millions$ 65.683  Millions
Adial Pharmaceuticals Inc   0.15 $ 0.492  Millions$ 3.276  Millions
Zevra Therapeutics Inc   0.15 $ 12.800  Millions$ 85.807  Millions
Biodexa Pharmaceuticals Plc  0.15 $ 0.463  Millions$ 3.162  Millions
Amphastar Pharmaceuticals Inc   0.14 $ 75.885  Millions$ 528.658  Millions
Opko Health Inc   0.14 $ 213.421  Millions$ 1,561.648  Millions
Regulus Therapeutics Inc   0.14 $ 4.511  Millions$ 33.291  Millions
89bio Inc   0.13 $ 19.691  Millions$ 151.832  Millions
Ligand Pharmaceuticals Incorporated  0.13 $ 76.695  Millions$ 597.485  Millions
Longeveron Inc   0.13 $ 2.605  Millions$ 20.503  Millions
Beigene ltd   0.12 $ 538.117  Millions$ 4,383.355  Millions
180 Life Sciences Corp  0.12 $ 1.309  Millions$ 11.344  Millions
Qualigen Therapeutics Inc   0.12 $ 1.011  Millions$ 8.767  Millions
Bicycle Therapeutics Plc  0.11 $ 30.315  Millions$ 270.783  Millions
Aldeyra Therapeutics Inc   0.10 $ 15.835  Millions$ 151.008  Millions
Xilio Therapeutics Inc   0.09 $ 9.832  Millions$ 105.647  Millions
Renovaro Inc   0.09 $ 5.926  Millions$ 66.899  Millions
Regeneron Pharmaceuticals Inc   0.09 $ 1,981.400  Millions$ 22,664.000  Millions
Trevi Therapeutics Inc   0.09 $ 9.151  Millions$ 107.459  Millions
Affimed N v   0.08 $ 13.089  Millions$ 171.265  Millions
Enlivex Therapeutics Ltd   0.07 $ 4.194  Millions$ 56.841  Millions
Spruce Biosciences Inc   0.07 $ 4.915  Millions$ 68.486  Millions
Proqr Therapeutics N v   0.07 $ 4.784  Millions$ 72.927  Millions
Celyad Oncology Sa  0.06 $ 0.289  Millions$ 4.835  Millions
Atai Life Sciences N v   0.06 $ 14.702  Millions$ 265.766  Millions
Cns Pharmaceuticals Inc   0.05 $ 0.410  Millions$ 8.133  Millions
Verona Pharma Plc  0.04 $ 9.768  Millions$ 230.466  Millions
Galmed Pharmaceuticals Ltd   0.04 $ 0.534  Millions$ 13.423  Millions

Date modified: 2023-03-26T06:46:31+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com